第一金融网主办
»您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

New post-hoc analysis of EMPA-REG OUTCOME examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease

2019/4/16 10:07:55  文章来源:文传商讯  作者:文传商讯
文章简介: Empagliflozin,inadditiontostandardofcare,hasthepotentialtoimproveeconomicoutcomesforpeoplewithtype2diabetesandestablishedcardiovasculard

Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1
Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME to predict clinical events and estimated costs for people with type 2 diabetes and diabetic kidney disease1
Empagliflozin is not indicated for the prevention of kidney disease

INGELHEIM, Germany & INDIANAPOLIS, Ind.--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® trial in a subgroup of 2,250 people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease.1 Results suggest that treatment with empagliflozin, in addition to standard of care, leads to fewer cardiovascular and renal events, and has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic kidney disease from the perspective of payers in the US.1 The results were presented at the ISN World Congress of Nephrology 2019 on 13 April in Melbourne, Australia.

Currently, there are more than 425 million people living with diabetes worldwide, 30-40 percent of whom are at risk of developing diabetic kidney disease.2,3 Furthermore, one third of people with diabetic kidney disease are at risk of progressing to end-stage kidney disease.3 Type 2 diabetes and diabetic kidney disease independently increase the risk of developing cardiovascular disease, with up to 1.2 million deaths from cardiovascular disease attributed to impaired kidney function.4 This progression of diabetic kidney disease among people with type 2 diabetes imposes substantial medical care costs.4 Typically, high-income countries spend more than 2-3 percent of their annual healthcare budget on the treatment of end-stage kidney disease.4

“Diabetic kidney disease occurs in up to 40 percent of people living with type 2 diabetes, many of whom are at substantial risk of experiencing kidney failure. This places a huge burden, not only on the patient’s life and the lives of their loved ones, but also on healthcare systems,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “We are encouraged by this latest analysis of the EMPA-REG OUTCOME® trial, which suggests that empagliflozin has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic kidney disease.”

Empagliflozin is not indicated for the prevention of kidney disease.

Cost effectiveness analysis is a conventional method of evaluating the economic impact of a treatment. The results were garnered using a simulation economic model to predict clinical events and estimated costs for the EMPA-REG OUTCOME® trial subgroup of patients with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease receiving empagliflozin with standard of care versus standard of care alone.1 The modeling and simulation of cost effectiveness was performed using the cost per episode of certain diabetes-related clinical events and health utilities in the US associated with these events. Patients receiving empagliflozin were predicted to experience fewer of these clinical events, including progression of albuminuria (presence of the protein albumin in the urine), composite renal outcomes, hospitalisation for heart failure and cardiovascular deaths. Additionally, patients taking empagliflozin with standard of care were projected to survive 1.37 years longer compared to standard of care alone. This sensitivity analyses showed that, from a US perspective, empagliflozin could be a cost effective option for 99 percent of people with type 2 diabetes and cardiovascular disease at a threshold of $100,000/quality-adjusted life years (QALYs).1*†

“Boehringer Ingelheim and Eli Lilly and Company are committed to addressing the high, unmet clinical need for additional therapies to reduce the risk of kidney disease progression and cardiovascular disease in people with kidney disease, irrespective of whether or not they have diabetes,” said Sherry Martin, M.D., Vice President, Medical Affairs, Lilly Diabetes. “We are looking forward to validating the results presented today with the patient outcomes in EMPA-KIDNEY, which investigates whether empagliflozin could help improve the lives of people living with kidney disease.”

In the landmark EMPA-REG OUTCOME® trial, empagliflozin showed promising results related to the reduction in the relative risk of new onset or worsening kidney disease.5 Based on these insights, Boehringer Ingelheim and Lilly have initiated an academic collaboration with the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU) to conduct EMPA-KIDNEY.6 The study investigates the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death in people with established chronic kidney disease with and without diabetes. Recruitment for the trial started in 2019 with the first results expected in 2022.6

About diabetic kidney disease
Diabetic kidney disease is a progressive decline of kidney function over time that occurs in 30-40 percent of all people with diabetes.3 One third of people with diabetic kidney disease may develop end-stage kidney disease, also known as kidney failure.3 Once end-stage kidney disease is reached, affected individuals have to undergo kidney replacement treatments, such as chronic dialysis or kidney transplantation.7 Since there is currently no approved treatment available to specifically reduce kidney disease progression and cardiovascular death, the overarching unmet medical need for new treatment options for people with kidney disease is evident.

About EMPA-KIDNEY: The study of heart and kidney protection with empagliflozin6
EMPA-KIDNEY is a multinational randomised, double-blind, placebo-controlled clinical trial. It is designed to evaluate the effect of empagliflozin on clinically relevant outcomes: kidney disease progression and cardiovascular mortality risk. The primary outcome is defined as time to a first event of either a cardiovascular death or kidney disease progression, defined as end-stage kidney disease (the need for kidney replacement therapy such as, dialysis or kidney transplantation), a sustained decline in eGFR to <10mL/min/1.73m2, renal death or a sustained decline of ≥40 percent in eGFR from randomisation. EMPA-KIDNEY includes people with established chronic kidney disease both with and without diabetes receiving current standard of care.

The study is conducted in selected countries representing a global footprint and aims to randomise approximately 5,000 participants to receive either empagliflozin 10mg once daily or placebo, on top of standard of care.

About EMPA-REG OUTCOME® (NCT01131676)5
EMPA-REG OUTCOME® was a long-term, multicenter, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10mg or 25mg once daily) added to standard of care compare with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The overall safety profile of empagliflozin was consistent with that of previous trials.

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.8,9,10

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes

* Quality-adjusted life years (QALYs) reflect a patient’s health by weighting life years lived with a health-related utility score, which puts a value on the reduction in a patient’s quality of life

† $100,000/QALY is the threshold for cost-effectiveness analysis in the US. This figure is based on an estimate of the cost-effectiveness of dialysis for chronic kidney disease

 

分享到:
第一金融网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  深圳暴雨引发洪水已致9人死亡2人失联 搜救正在进
     陕西回应兵马俑手指被盗案:将索赔并追究民事责
    [银行]  中国一银行高管受贿¥4000万 豪车房产居多 曾经
     建设银行山东分行原行长薛峰受贿4320余万获刑13
    [股票]  3月CPI、PPI冲击!股市大跳水 机构解读
     又是旧闻新炒!神秘真菌引爆A股,央视辟谣后继续
    [基金]  格力70亿巨资封涨停 770只基金持仓400多只重仓
     什么是理财型基金?理财型基金应该如何选择呢?
    [保险]  800万保险代理人被骗子盯上 齐保网涉嫌诈骗被端
     中国社保降费综合方案出炉!5月起民众社保将有变
    [期货]  原油期货上市一周年 上期所原油期货价格指数今正
     3月1日国内期油涨1.77% 汽油价格每吨上调270元
    [股评]  谁在狂奔入场?深交所刚刚发布权威数据:1000万
     自营盘动向浮出水面 券商 “抄底”医药股
    [港股]  中国移动:4G基站数达到241万个 超过电信、联通
     小米集团遭雷军套现45亿港元? 半年市值蒸发300
    [美股]  京东可能裁员8%或超过1.2万人 股价放量回落
     李彦宏:最后一公里自动驾驶技术将挤压传统汽车
    [外汇]  人民币对美元汇率中间价报6.8526元 下调124个基
     截至2018年12月末 中国外汇储备规模为30727亿美
    [债券]  “中国大妈”爱上的这款新理财 为啥冷暖两重天?
     寰球视野\人币债券纳国际指数有助吸引外资流入
    [黄金]  刘智辛:欧美货币持稳,黄金日线三连阳,原油多
     央行连续4个月耗资120亿元爆买黄金!全球都在买
    [理财]  马云:员工能在996的公司是福报
     住高速附近婴幼儿发育迟缓? 报告称污染可致智力
    [信托]  信托业一批防风险新规将出台
     民生信托撤回对乐视控股及贾跃亭执行申请 已追回
    [房产]  买房的要注意了!这些城市限售楼盘将迎来"解冻"
     韩咏红:中国给户籍“松绑”救房市?
    [汽车]  比亚迪9款新车同步上市 覆盖多种动力系统
     车市迎今年第三波降价潮 南北大众、上汽通用全系
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息